Capsugel scientists will discuss a range of advancements—including bioavailability enhancement and multi-particulate technologies, dry powder inhalation (DPI) technologies, and alternate-polymer and other specialized capsule technologies—at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs Nov. 2 to 6 in San Diego, Calif. The company will also showcase specialized equipment to support key technologies in encapsulation and bioreactor process control.
"It’s an exciting time to be a scientist at Capsugel. Our advanced science and engineering, expanded technology offerings, and the growing synergies between our Hard Capsule and Dosage Form Solutions (DFS) business units are leading to new opportunities to create value for our customers,” said Keith Hutchison, Ph.D., senior vice president of research and development at Capsugel. “At AAPS, we look forward to discussing our approach to addressing customers’ most-pressing formulation challenges, including low and variable drug absorption, high-potency/low-dose requirements and modified drug release profiles and to demonstrating our unique ability to design, develop and manufacture both state-of-the-art capsules and finished dosage forms."
Company scientists will present 20 technical posters and host a series of seminars on key innovations. Highlights include:
- New lipid multi-particulate (LMP) technology, based on Capsugel’s proprietary melt-spray congeal processing, providing the functionality of lipid-based formulations with the patient and consumer benefits associated with a multi-particulate drug delivery;
- Coni-Snap® sprinkle capsules designed for populations with swallowing difficulties, offering reproducible ease of opening for patients and caregivers;
- Integrated formulation and specialized capsule offering for Inhalation products, including particle engineering for optimized formulations and specialized DPI capsules for pulmonary delivery;
- Advancements in spray-dried dispersion and other bioavailability-enhancement technologies, pioneered by Bend Research, now a division of Capsugel Dosage Form Solutions.
Specialized equipment that will be featured at the booth includes Capsugel’s new Modular Automated Sampling Technology™ platform, or MAST, and its Xcelodose® precision powder micro-dosing system. MAST is an automated, aseptic bioreactor sampling system that will help advance the bioprocess industry toward real-time testing, predictive control and overall bioprocess guidance. Capsugel’s Xcelodose® system shortens drug development time, speeds first-in-human trials and lowers costs by reducing the need for formulation and stability studies before API proof of concept is established.
Visit Capsugel’s booth #1422 to learn about innovative dosage technology and manufacturing solutions for the pharmaceutical industry.